Evidence map›Paper›PMID 41184622›Full record

ArticleActa pharmacologica Sinica2026

Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase.

Lei Gong, Chang-Xiao-Feng Liu, Jian-Hua Cheng, Jing Guo, Bin Li, Hong-Yun Wang, Meng Liu, Jia-Lin Wang, Xue-Jing Li, Qiu-Yue Fang and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lei Gong *Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Chang-Xiao-Feng Liu *Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Jian-Hua ChengBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Jing GuoDepartment of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, 100070, China.
Bin LiBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Hong-Yun WangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Meng LiuBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Jia-Lin WangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Xue-Jing LiBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Qiu-Yue FangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Zhao-Yi YiBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Chu-Zhong LiBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Ya-Zhuo ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Wei-Yan XieBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. weiyanxie@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dopamine receptor agonist (DA)-resistant prolactinoma presents a significant clinical challenge, highlighting the need for novel therapeutic strategies. Deguelin is a rotenoid compound derived from several plant species with unique antitumor effects. In this study we investigated the efficacy of deguelin on DA-resistant prolactinoma and elucidated its antitumor mechanisms. We showed that deguelin concentration-dependently inhibited cell viability, proliferation and prolactin secretion, and promoted apoptosis and cell cycle arrest in two prolactinoma tumor cell lines GH3 and MMQ. In CCK-8 assay, the IC

Indexed as

Antineoplastic AgentsPituitary NeoplasmsProlactinProlactinomaAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalCyclic AMP Response Element-Binding ProteinHumansMaleMiceMice, Inbred BALB CMice, NudeOrnithine DecarboxylaseAntineoplastic AgentsCyclic AMP Response Element-Binding ProteindeguelinOrnithine DecarboxylasePhosphatidylinositol 3-KinasesProlactinProto-Oncogene Proteins c-aktRotenoneapoptosisCREB3L1DA-resistant prolactinomadeguelinornithine decarboxylasePI3K/AKT signaling

Identifiers

PMID41184622
PMCPMC13018649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.